Citatuzumab bogatox - Sesen Bio

Drug Profile

Citatuzumab bogatox - Sesen Bio

Alternative Names: VB6-845; VB6-845d

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viventia Biotech
  • Developer Sesen Bio
  • Class Antineoplastics; Immunoconjugates; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 24 Nov 2017 Phase I development is underway for Solid tumours (Eleven Therapeutics pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top